Just on valuation this what we know so far
current revenues from monitoring and services = USD 5mio annual
McDade estimated Q1 testing and pathology = USD30mio extrapolate * 4 = USD$120mio p.a
Serology agreement estimated monthly revenue of USD$4mio *12 = USD$48mio p.a
IF all this comes to fruition on a 10x revenue to price estimate let’s say $150mio x10 or $1.5bio in market cap
$1.5bio / 13.5mio shares on issue (not accounting for convertible note dilution) = $111per share
take with a huge grain of salt given execution track record and previous announcements that eventuate into nothing but seemingly this stock would be massively discounted to announced earnings
keep in mind false and misleading statements are securities fraud and carry up to 3 years jail + $10mio fine
- Forums
- ASX - By Stock
- GMV
- IPO update
IPO update, page-1171
-
- There are more pages in this discussion • 399 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online